Skip to main content

A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer

Publication ,  Journal Article
Enzinger, PC; Burtness, B; Hollis, D; Niedzwiecki, D; Ilson, D; Benson, AB; Mayer, RJ; Goldberg, RM
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2010

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15

Publisher

AMER SOC CLINICAL ONCOLOGY

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Enzinger, P. C., Burtness, B., Hollis, D., Niedzwiecki, D., Ilson, D., Benson, A. B., … Goldberg, R. M. (2010). A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Enzinger, P. C., B. Burtness, D. Hollis, D. Niedzwiecki, D. Ilson, A. B. Benson, R. J. Mayer, and R. M. Goldberg. “A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.” JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010).
Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, et al. A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. JOURNAL OF CLINICAL ONCOLOGY. 2010 May 20;28(15).
Enzinger, P. C., et al. “A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2010.
Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, Mayer RJ, Goldberg RM. A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2010 May 20;28(15).

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15

Publisher

AMER SOC CLINICAL ONCOLOGY

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences